WinstonWınston
Coloplast A/S logo

Coloplast A/S

COLO-B.CO
52
Medical - Instruments & Supplies · Healthcare
Price
kr 437.50
+11.40 (+2.68%)
Market Cap
kr 98.57B
Exchange
NASDAQ Copenhagen
Winston Score
52
Winston is curious
Mixed quality — meaningful strengths and weaknesses.
Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+5.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 213.2M (2021) → 225.4M (2025)

Coloplast is a Danish medical device company that makes products for people with intimate health conditions — things like ostomy bags (for people who have had bowel surgery), catheters, wound care dressings, and continence products. Its customers are mostly patients, hospitals, and home care providers across the world. Coloplast is one of the largest companies in the world focused specifically on ostomy and continence care.

The company sells its products directly to healthcare systems and through distributors, earning revenue from ongoing product purchases rather than one-time sales — patients typically need these supplies every day for life. Coloplast operates in over 40 countries, with Europe as its largest market, though it has been growing in the United States and emerging markets. Its main competitive advantages are strong brand loyalty among patients and clinicians and deep specialization in a niche that larger medical device companies tend to ignore. The key growth risk is pricing pressure from healthcare systems looking to cut costs on consumable medical supplies.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+2.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-206.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$900M/ year

Flat (+4% vs prior year)

3.2% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

36.6%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$1.2B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Coloplast A/S is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
42.9%
Healthy — 42.9% gross margin
Operating Margin
25.4%
Excellent — 25.4% operating margin
ROCE
5.0%
Weak — 5.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+0.9%
Nearly flat sales (+0.9% YoY)
EPS YoY
-53.7%
Earnings shrinking (-53.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
361%
Turns 361% of profit into real cash
FCF Margin
21.5%
Converts sales into free cash efficiently (21.5%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
1.82
Elevated debt (1.82)
Interest Cover
7.47x
Adequate interest coverage (7.5x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
46.8x
Expensive — P/E 46.8

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+31.8
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (46.8 → 15.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
5.31%
Healthy income — 5.31% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend Growth
+9.8%
Dividend growing modestly (9.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial